Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study.

Amir I Tukhvatulin, Olga V Zubkova + Show 26 more

Open Access

https://doi.org/10.3389/fimmu.2023.1228461

Copy DOI

Journal: Frontiers in Immunologie	Publication Date: Aug 1, 2023
Citations: 2	License type: CC BY 4.0

Abstract

ClinicalTrials.gov, NCT04954092, LP-007632.

Full Text

Published version (

Free)

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Paper Title

Journal

Date

Author